15 Septiembre 2019

Navega Therapeutics has been recognized as a TechConnect Defense Innovation Awardee

Navega will showcase and present on Tuesday October 8 at 2:50pm.


Navega Therapeutics has been recognized as a 2019 TechConnect Defense Innovation Awardee at next month's DefenseTechConnect Summit and Expo in National Harbor, MD. Navega’s technology received this Award because it placed in the top 15% of submitted challenge technologies as ranked by the Selection Committee. As an Awardee, Navega is listed on their 2019 Awards page:

Veterans have a higher rate of chronic pain (50-60%), rates that exceed the reported 30% national average of chronic pain within the general American population ( Despite their side-effects and limited efficacy, opioids have been a preferred treatment for chronic pain among both private and VA prescribers in recent years. Because of the prevalence and complexity of chronic pain in the veteran population, VHA developed and deployed two initiatives in 2014 to improve the safety and management of chronic pain in veterans: the Opioid Safety Initiative (OSI), and enabling VA providers to participate in state prescription drug monitoring programs (PDMP). Therefore, Navega’s approach can ameliorate the suffering and potential addiction of VA. In 2013, the VA Principal Deputy Under Secretary for Health informed Congress that more than 50 percent of veterans receiving care at Veterans Health Administration (VHA) facilities were affected by chronic pain ( In addition, since our approach is long lasting, Navega’s therapy could be used to pre-emptively decrease pain before soldiers are deployed in action. Thus, we are proud to announce our selection as a 2019 TechConnect Defense Innovation Awardee.


About Defense TechConnect Summit |To learn more about the Defense TechConnect Summit and Expo at National Harbor, MD, one of the most well-attended defense events of the year, visit: The annual TechConnect Defense Innovation Awards recognizes the top 15% of submitted Challenge technologies as ranked by the Selection Committee.

About Navega Therapeutics Inc. | Navega is a preclinical stage company pursuing a radically different approach to treat chronic pain and tackle the opioid epidemic. Our gene therapy platform has the advantage of being highly specific and long-lasting, which has not been achieved by small molecules thus far. Our approach includes addressing different types of pain in order to improve the quality of life of millions of patients.

To learn more visit or contact us at